

Table S1. Synovial fluid cytokine concentrations (pg/mL) in the examined patients with OA prior to HTO surgery

Cytokine	SVF subgroup at baseline (n=10) Me [IQR]	PRP subgroup at baseline (n=10) Me [IQR]	P (Mann-Whitney U-test)
IFN γ	6.9 [0.0;13.8]	0.0 [0.0;4.1]	n.s.
IL12P40	13.8 [3.8;32.4]	21.8 [10.7;38.4]	n.s.
IL-12P70	4.5 [0.0;7.1]	3.0 [0.0;4.3]	n.s.
IL-1 β	58.5 [42.5;96.0]	0.0 [0.0; 6.8]	<0.01*
IL-6	373.8 [142.7;715.7]	125.1 [45.3;644.9]	n.s.
IL-7	30.4 [14.3;39.5]	9.0 [2.3; 37.6]	n.s.
TNF α	13.3 [11.7;18.4]	12.2 [9.8;16.3]	n.s.
IL-10	12.4 [9.6; 14.4]	8.9 [4.4; 15.6]	n.s.
IL-1RA	36.4 [26.0; 56.0]	40.9 [25.3;56.5]	n.s.
IL-4	6.9 [0.0; 11.7]	58.4 [10.4; 87.0]	<0.01*
EGF	0.0 [0.0; 35.3]	16.4 [0.0;23.8]	n.s
FGF-2	167.5 [93.5;186.0]	171.1 [100.7; 187.7]	n.s
G-CSF	14.6 [9.3;24.5]	19.0 [8.0;28.0]	n.s
Flt-3L	149.2 [131.2;211.6]	149.6 [108.9;167.4]	0.60
PDGF-AA	21.2 [20.3;27.9]	14.4 [8.0;26.0]	n.s
PDGF-AB/BB	39.6 [27.2;61.8]	27.8 [22.2;64.5]	n.s
VEGF	263.9 [243.5;286.0]	103.0 [61.7; 167.7]	<0.01*
Eotaxin	71.9 [52.8;81.9]	54.5 [43.9; 60.5]	n.s
Fractalkine	74.2 [68.9;84.9]	133.2 [87.4;176.9]	0.07
GRO	189.5 [168.7;242.1]	190.1 [137.3;358.1]	1.00
MCP-3	45.8 [33.9;66.5]	93.1 [61.3; 128.1]	0.01*
MDC	658.1 [289.3;942.4]	558.2 [480.0; 782.1]	0.80
IL-8	318.0 [89.2;425.3]	189.3 [76.5;304.1]	n.s
IP-10	1220.0 [950.6;1569.0]	1295.0 [1100.0;2680]	n.s
MCP-1	1328.0 [1100.0;1755.0]	1767 [1074;2357]	n.s
MIP-1 α	12.4 [0.0;17.2]	18.2 [10.0;30.0]	n.s

MIP-1 β	33.8 [28.8;61.5]	40.9 [29.4;51.6]	0.60
RANTES	445.6 [325.5;532.1]	631.6 [332.4;1770.0]	n.s
IFN α 2	16.9 [4.9;47.7]	25.7 [21.0;37.6]	n.s
IL-15	26.9 [22.6;34.5]	17.5 [16.8;23.6]	0.07
sCD40L	21.3 [17.9;27.0]	36.6 [17.9;72.0]	n.s

Note: Me [IQR], median [interquartile range, 25th, 75th percentiles]

Table S2. Spearman's rank correlation coefficients (r) ($p<0.05$) are shown for cytokine concentrations observed in the synovial fluid of patients with OA at baseline prior to SVF injection.

Table S3. Spearman's rank correlation coefficients (r) ($p<0.05$) are shown for cytokine concentrations observed in the synovial fluid of patients with OA at baseline prior to PRP injection.